O-1A Guide
O-1A for Biotech Founders: Evidence Beyond the Patent
Biotech founders typically have strong patent portfolios and thin publication records — an unusual combination for O-1A purposes. Here is how to build a complete extraordinary ability argument from the clinical, commercial, and scientific record a founder actually has.
Why the founder profile creates a distinct O-1A challenge
Biotech founders often enter the O-1A process with one strong credential — a patent portfolio — and several under-documented criteria. The patent is valuable O-1A evidence under the original contributions criterion at 8 C.F.R. § 214.2(o)(3)(iii)(B)(5), which requires original scientific, scholarly, or business-related contributions of major significance in the field. A patent establishes that the petitioner's invention was deemed novel and non-obvious by the USPTO, but the patent grant itself does not establish that the contribution is of major significance in the field. That argument requires additional evidence: citations, licenses, clinical applications, publications describing the technology's impact, or expert letters explaining how the patented invention advanced the state of the art.
Founders present a distinct challenge because their career trajectory has typically moved away from academic publication and toward company formation, fundraising, team building, and regulatory navigation. The O-1A criteria were designed largely with academic and research professionals in mind, and the evidentiary landscape for a researcher-turned-founder often has significant gaps. A founder who left a research position to start a company several years ago may have a modest recent publication record, no current institutional affiliation to generate press and recognition, and compensation structured partly as equity rather than salary — which complicates the high salary criterion. Understanding these gaps in advance allows the petition to address them proactively rather than leaving the adjudicator to identify them.
Despite these challenges, biotech founders often have significant O-1A evidence that requires careful framing rather than additional credentials. A founder who has served on a scientific advisory board for another company or a regulatory advisory committee is satisfying the judging criterion. A founder whose company has attracted coverage in the biotech trade press — STAT News, BioCentury, FierceBiotech, Endpoints News — has press criterion evidence. A founder whose cash compensation includes a salary component that exceeds the relevant benchmark may be able to establish the high salary criterion even if the total compensation structure includes equity. The petition requires a thorough audit of the founder's full career record, not just the credentials most visible on a CV.
Patents and original contributions
The original contributions criterion under O-1A requires original scientific, scholarly, or business-related contributions of major significance in the field. A patent satisfies the originality threshold automatically — the USPTO's examination process confirms that the invention is novel and non-obvious. But major significance is a separate showing. USCIS has interpreted this standard to require evidence that the contribution has been recognized by others in the field as important, not just that the petitioner made it. Evidence of major significance includes patent licenses to third parties (especially major pharmaceutical companies or research institutions), independent publications citing the petitioner's patent or technology, clinical trials using the patented method or compound, and FDA filings that reference the technology as part of an approved or advancing program.
Biotech founders who have not published extensively after leaving academia often have original contributions evidence embedded in the company's development history. A therapeutic candidate that has advanced through Phase I or Phase II clinical trials demonstrates that the underlying science was sound enough to attract IND approval from the FDA and investor capital to fund trials — both forms of third-party validation of the technology's significance. The petition brief should narrate the technology's development arc from research discovery through clinical application, citing publicly available materials such as ClinicalTrials.gov entries, FDA correspondence where publicly available, and investor announcements to corroborate the timeline and the petitioner's central role in it.
Founders with prior academic careers may have publication records from that period that remain citable evidence even years after company formation. A publication in Nature Biotechnology, Cell, Science, or the Journal of the American Chemical Society that has accumulated substantial citations in the primary literature remains strong original contributions evidence regardless of when it was published. The petition should include a Google Scholar profile or equivalent showing citation counts and, where applicable, the publication's role in subsequent research — noting if the cited paper has been referenced by other highly cited papers, which is a measure of scientific impact beyond raw citation count. A paper cited substantially in the primary literature speaks to the field's recognition of the contribution's importance.
Published research and scholarly recognition
The scholarly articles criterion under O-1A covers published material in professional or major trade publications relating to the petitioner's work in the field. For biotech founders, qualifying publications include original research articles in peer-reviewed journals, review articles in high-impact journals, preprints that have gained wide citation in the research community, and invited perspective pieces or commentaries in high-impact journals. Invited commentaries are particularly useful because they represent a form of peer recognition — the journal's editors selected the petitioner to write because they regarded the petitioner as an authority worth hearing from, which establishes recognition beyond the contribution itself.
Founders who published nothing after leaving academia have a dated scholarly record, and adjudicators sometimes raise concerns about whether older publications establish current standing in the field. The petition can address this by pairing the academic publication record with more recent evidence of engagement with the scholarly community: peer review invitations from recognized journals, conference presentations at major scientific meetings, and citations of the petitioner's earlier work in papers published within the last two or three years. Recent citations from active researchers establish that the petitioner's prior work continues to be regarded as significant by the scientific community, even if the petitioner is no longer producing new publications.
Industry publications in the biotech trade press serve a dual role in O-1A petitions. Publications like STAT News, BioCentury, FierceBiotech, Endpoints News, and GEN (Genetic Engineering and Biotechnology News) can satisfy the press criterion under 8 C.F.R. § 214.2(o)(3)(iii)(B)(3), which requires published material in professional or major trade publications relating to the petitioner and their work. They can also serve as corroborating evidence for the original contributions and critical role criteria by documenting that the field has recognized the petitioner's work as notable. Articles that analyze the petitioner's technology, cover a clinical milestone, or identify the petitioner as a scientific leader in a relevant research area are strong exhibits for multiple criteria simultaneously.
Judging, advisory boards, and peer review
The judging criterion under O-1A at 8 C.F.R. § 214.2(o)(3)(iii)(B)(4) requires participation as a judge of the work of others, either individually or on a panel, in the same or an allied field. For biotech founders, the most common qualifying forms are grant review panels, NIH study sections, peer review for academic journals, and service on scientific advisory boards for other companies. NIH study sections are particularly strong evidence because membership requires nomination and appointment by NIH program officers — a formal recognition by a federal scientific agency that the petitioner has expertise worthy of trust in evaluating grant applications from active researchers.
Scientific advisory board service for another biotech company or research institution is an increasingly important piece of the founder's O-1A record. When the petitioner serves on an external SAB — particularly for a company in a related therapeutic or technological area — they are exercising expert judgment about that company's science, and the company has recognized them as having expertise worth compensating. The petition exhibit for SAB service should include a copy of the SAB agreement or appointment letter, a brief description of the company and the nature of the petitioner's advisory role, and corroborating evidence such as press releases announcing the SAB formation or the company's published materials listing the SAB membership, confirming the appointment from a source independent of the petitioner.
Peer review invitations from recognized journals also satisfy the judging criterion when properly documented. The petition exhibit should include printouts of peer review invitation emails with manuscript author information redacted for confidentiality, confirmation of the petitioner's reviewer status from the journal's editorial system, and a brief description of each journal's standing in the field. Peer review for journals with strong impact factors in the petitioner's specific subdiscipline is straightforwardly qualifying. Peer review for very low-impact or predatory journals is unlikely to satisfy the criterion even if technically within the field. The petition brief should explain each journal's standing so the adjudicator can assess the peer recognition that invitation represents.
Critical role, press coverage, and high compensation
The critical role criterion at 8 C.F.R. § 214.2(o)(3)(iii)(B)(7) requires a critical or essential role in organizations or establishments with distinguished reputations. For a biotech founder, the critical role is typically the founder-CEO or CSO position at the company they founded. But the company itself must have a distinguished reputation — which for a startup may be established through its scientific recognition, commercial milestones, or clinical advancement. A company at the seed stage with no significant external recognition is difficult to characterize as a distinguished establishment. A company that has completed a Series A or B with recognized institutional investors, published data in peer-reviewed journals, and received IND clearance from the FDA has substantially more to work with.
Press coverage in the biotech trade press is available to founders in a way that may not be available to pure academic researchers. A company that has completed a significant funding round, published important clinical data, or entered a major partnership will typically receive coverage in STAT News, FierceBiotech, or BioCentury. That coverage, when it profiles the founder-CEO as the scientific and strategic leader of the company, satisfies the press criterion under O-1A. The press exhibit for each article should include the article itself, documentation of the outlet's standing in the biotech industry, and a brief annotation in the petition brief connecting the article to the recognition inference required by the criterion.
The high salary criterion is complicated for founders whose compensation includes significant equity. The criterion at 8 C.F.R. § 214.2(o)(3)(iii)(B)(8) refers to remuneration for services evidenced by contracts or offers. If the founder takes a market salary — as founders of venture-backed companies often do after a Series A — that cash salary should be compared against BLS OEWS data for chief executives in the relevant geography and industry sector. If the founder's cash compensation falls below the 90th percentile benchmark, the petition brief can address the equity component as evidence of the market's valuation of the petitioner's expertise, while being explicit that the primary salary comparison uses the cash compensation figure.
Building the complete founder petition
The most effective biotech founder O-1A petition leads with original contributions because the patent portfolio and the technology's development arc are typically the strongest part of the record. The original contributions section should be detailed — not just listing patent numbers but narrating the technology's development from research concept through clinical application, with corroborating documentation at each stage. Expert letters for the original contributions section should come from scientists in the relevant field — oncology, gene therapy, proteomics, or the specific subdiscipline — who can assess the significance of the petitioner's invention relative to the state of the art. A letter from a department chair or principal investigator at a research university in the relevant discipline carries more weight than a general letter of support.
For founders with thin publication records, the petition should lean on press coverage, SAB service, peer review history, and critical role documentation. Three or four expert letters from senior scientists in the field — addressing the original contributions and the petitioner's standing as an innovator — can partially substitute for a deep publication record if each letter makes specific comparative claims rather than general endorsements. The petition brief should acknowledge the founder's career trajectory explicitly: noting when the petitioner transitioned from academic research to company formation, and arguing that the company's clinical and scientific achievements are the practical manifestation of the research excellence that underpins the O-1A claim.
The support brief for a biotech founder petition should include a totality section that synthesizes all the evidence into the extraordinary ability argument. Each criterion section makes the case for that criterion in isolation; the totality section argues that no single criterion captures the full significance of the petitioner's record. A founder who holds a foundational patent in their therapeutic area, has served on NIH study sections, has been covered in the biotech trade press, and has advanced a therapeutic candidate through Phase I clinical trials has achieved a level of recognition and scientific contribution that the totality-of-the-record standard is designed to capture. The brief should make that argument explicitly, because adjudicators are most likely to reach a favorable conclusion when the synthesis has been done for them.